Tag: FDA

Bioinformatics Software QA Engineer (Remote Option) at Genentech

The Position Genentech, a member of the Roche group and founder of the biotechnology industry, is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. To solve the world’s most complex health challenges, we ask bigger questions that challenge our industry and…

Continue Reading Bioinformatics Software QA Engineer (Remote Option) at Genentech

The Promise of RNA-Based Therapies

Published a day ago Submitted by CRB Decades of scientific progress in understanding the root cause of many formerly intractable diseases has opened up new treatment options, namely through RNA-based therapies. This second wave of biopharma, in which our understanding of the ways coding portions of our genome relate to…

Continue Reading The Promise of RNA-Based Therapies

Sickle Cell Disease Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Sickle Cell Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Sickle Cell Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Sickle Cell Disease Overview Sickle Cell Disease is a group of inherited red blood cell disorders that…

Continue Reading Sickle Cell Disease Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

IMUNON, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)

The following discussion and analysis of our financial condition and results of operations This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are not limited to, those discussed above…

Continue Reading IMUNON, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line. New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to chimeric antigen receptor (CAR) T-cell therapy,…

Continue Reading Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

Rhythm Pharmaceuticals Announces Publication of Results

— Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome — BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia…

Continue Reading Rhythm Pharmaceuticals Announces Publication of Results

Biogen Seeks A Preliminary Injunction In Natalizumab BPCIA Case Against Sandoz – Patent

02 November 2022 Goodwin Procter LLP To print this article, all you need is to be registered or login on Mondaq.com. Biogen seeks a preliminary injunction in its BPCIA case against Sandoz related to Sandoz’s proposed biosimilar of TYSABRI (natalizumab). On October 20, 2022, the Court…

Continue Reading Biogen Seeks A Preliminary Injunction In Natalizumab BPCIA Case Against Sandoz – Patent

Breast Implant-Associated Cancers: What Providers and Patients Need to Know

Patients with breast implants are at risk of developing squamous cell carcinoma (SCC) and various types of lymphoma in the capsules around the implants, according to the US Food and Drug Administration (FDA).1  These cancers appear to be rare, but patients and clinicians should be aware of the risk, according…

Continue Reading Breast Implant-Associated Cancers: What Providers and Patients Need to Know

Applications for Epcoritamab Submitted to FDA and EMA in Relapsed/Refractory LBCL/DLBCL

Patients with relapsed/refractory large B-cell lymphoma may benefit from epcoritamab, the biologics license applications of which were submitted to the FDA. A biologics license application for subcutaneous epcoritamab (DuoBody-CD3xCD20) was submitted to the FDA for patients with relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more lines of systemic therapy…

Continue Reading Applications for Epcoritamab Submitted to FDA and EMA in Relapsed/Refractory LBCL/DLBCL

The Next Generation of COVID-19 Vaccines and Boosters

The US Food and Drug Administration (FDA) emergency use authorization (EUA) for the first vaccines combating COVID-19 was a milestone in the 2020 pandemic. Due to this provision, Pfizer-BioNTech’s BNT162b2 (Comirnaty), Moderna’s mRNA-1273 (Spikevax), and Johnson & Johnson/Janssen’s COVID-19 vaccine (Ad26.COV2.S) received EUAs for COVID-19 prevention in December 2020, February…

Continue Reading The Next Generation of COVID-19 Vaccines and Boosters

MT-101 Granted Fast Track Designation by FDA for CD5+ Relapsed/Refractory Peripheral T-Cell Lymphoma

Patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma may derive benefit from MT-101, which was granted fast track designation by the FDA. The FDA has granted fast track designation to MT-101 for the treatment of patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma (PTCL), according to a press release from Myeloid Therapeutics….

Continue Reading MT-101 Granted Fast Track Designation by FDA for CD5+ Relapsed/Refractory Peripheral T-Cell Lymphoma

Mechano-Cas12a Assisted Tension Sensor (MCATS) for Massively Amplified Cell Traction Force Measurements

Abstract Cells transmit piconewton forces to mediate essential biological processes such as coagulation. One challenge is that cell-generated forces are infrequent, transient, and difficult to detect. Here, we report the development of Mechano-Cas12a Assisted Tension Sensor (MCATS) that utilizes CRISPR-Cas12a to transduce and amplify the molecular forces generated by cells….

Continue Reading Mechano-Cas12a Assisted Tension Sensor (MCATS) for Massively Amplified Cell Traction Force Measurements

Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.

Company to Develop StemVacs-V Anti-Angiogenesis Immunotherapy for Initial Treatment of Breast Cancer ELK CITY, Idaho, October 27, 2022–(BUSINESS WIRE)–Therapeutic Solutions International (TSOI) announced today formation of a Spin-Off Company, Res Nova Bio, Inc., dedicated to the development of cancer inhibiting anti-angiogenesis immunotherapies. Res Nova Bio has licensed from Therapeutic Solutions…

Continue Reading Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.

Lessons From ZUMA-7, BELINDA, and TRANSFORM

Dr. Brad Kahl Key Points: Historically, patients with diffuse large B-cell lymphoma (DLBCL) for whom frontline and salvage chemotherapy had failed had little chance of cure; now, 3 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—show promising prolonged disease-free survival. The ZUMA-7, BELINDA, and TRANSFORM trials compared…

Continue Reading Lessons From ZUMA-7, BELINDA, and TRANSFORM

Ibuprofen API Market to Hit USD 772.2 Mn by 2029 | Future Market Insights

The global Ibuprofen API Market surpassed US$ 626.2 Mn in 2022 and is anticipated to increase at a CAGR of 3% to reach US$ 772.2 Mn by 2029. as per the findings of a new Future Market Insights (FMI) study. The primary factors for the growth of the Ibuprofen API market include continuous demand for low-cost non-steroidal anti-inflammatory…

Continue Reading Ibuprofen API Market to Hit USD 772.2 Mn by 2029 | Future Market Insights

Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement. Pemigatinib (Pemazyre) showed a strong survival benefit in patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement, according to final…

Continue Reading Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma

It is time to start the renaissance of aptamers

Who here has heard of an aptamer? Most people by now would have heard of RNA and are likely to have been the recipient of a strand or two thanks to COVID vaccines. Macugen was the first RNA biotherapeutic approved by the US Food and Drug Administration (FDA) in 2004,…

Continue Reading It is time to start the renaissance of aptamers

Tafasitamab/Lenalidomide Shows Efficacy for 2+ Years in R/R DLBCL

Updated results from the L-MIND trial show continued efficacy and safety data for the combination of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma. Tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) showed long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who were treated for at…

Continue Reading Tafasitamab/Lenalidomide Shows Efficacy for 2+ Years in R/R DLBCL

Strata Oncology hiring Senior/Principal Bioinformatics Scientist in United States

JOB TITLE: Senior/Principal Bioinformatics Scientist DEPARTMENT: Software Engineering/Bioinformatics REPORTS TO: Sr. Director of Bioinformatics LOCATION: Ann Arbor, MI, or Remote At Strata our mission is to accelerate the impact of precision medicine for patients with cancer. Job Summary We’re seeking an experienced data scientist to join our Bioinformatics team. We…

Continue Reading Strata Oncology hiring Senior/Principal Bioinformatics Scientist in United States

There Are New FDA Safety Warnings About Breast Implants. Here’s What We Know : ScienceAlert

The US Food and Drug Administration (FDA) is now warning that breast implants filled with either silicone or saline may, on rare occasions, give rise to cancer in the scar tissue around breast implants. The safety notice was published this month and is based on an extensive review of the…

Continue Reading There Are New FDA Safety Warnings About Breast Implants. Here’s What We Know : ScienceAlert

How new COVID-19 vaccines work

; DAY New vaccines against COVID-19 begin to be authorized around the world. How do they work, who makes them? Update on these new serums.  Adaptation to the evolution of viruses The virus of the disease COVID-19, SARS-CoV-2 , has the ability to mutate, like other viruses. It is a…

Continue Reading How new COVID-19 vaccines work

Vaccines used to prevent monkeypox

The monkeypox virus is a DNA virus that belongs to the Orthopoxvirus genus. This genus comprises other viruses such as camelpox, cowpox, raccoonpox, skunkpox, variola, and vaccinia. While monkeypox was initially discovered in 1958 in monkeys, rodents are known to be its natural reservoir, and humans and other primates are often incidental…

Continue Reading Vaccines used to prevent monkeypox

Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model

In a recent study posted to the bioRxiv* server, researchers at the United States Army Medical Research Institute of Infectious Diseases evaluated the immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) deoxyribonucleic acid (DNA) vaccine, nCOV-S(JET), in rhesus macaques. A previous evaluation of this coronavirus disease 2019 (COVID-19)…

Continue Reading Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model

Dyadic International : Presentation | MarketScreener

Dyadic International (NASDAQ: DYAI) Next Generation Proteins for World Health C1 Vaccine Technology Presentation Mark Emalfarb, Founder & CEO Vaccine Technology Summit September 15-16, 2022 London UK Safe Harbor Regarding Forward-looking Statements Certain statements contained in this presentation are forward-looking statements within…

Continue Reading Dyadic International : Presentation | MarketScreener

US FDA issues cancer warning linked to breast implants

On Sept 8, 2022, the US Food and Drug Administration (FDA) issued a safety communication to highlight reports of squamous cell carcinoma and various lymphomas in the scar tissue, or capsule, that surrounds breast implants. The lymphomas are distinct from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), which is also…

Continue Reading US FDA issues cancer warning linked to breast implants

12 Careers for Life Scientists Outside of the Lab

Not everyone who completes a life sciences PhD wants to continue working in a laboratory or in research. They may just have grown out of it or found that the work isn’t what they thought it was. Or maybe they still love science and would rather find a different way…

Continue Reading 12 Careers for Life Scientists Outside of the Lab

Global Gene Therapy R&D Market Worth US$ 22,685.70 million by 2031: Visiongain Reports Ltd

Visiongain Reports Ltd Global Gene Therapy R&D Market Forecast 2021-2031: – Market Segment by Disease {Cancer, Rare Diseases (Oncologic, Non-Oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Hematology, Neurological, Diabetes Mellitus, Other Diseases}, Vector {Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-Viral (Naked DNA, Gene Gun, Electroporation, Lipofection)}, Techniques (Gene Augmentation Therapy, Gene Replacement…

Continue Reading Global Gene Therapy R&D Market Worth US$ 22,685.70 million by 2031: Visiongain Reports Ltd

For This AI Drug Developer, Look Beyond the Rally

A handful of trendy biotech stocks in early August got swept up in meme-stock mania. Relay Therapeutics  (RLAY)  wasn’t one of them — but it still surged. The unheralded drug developer uses artificial intelligence, machine learning, and a supercomputer to design precision medicines.  The biotech stock saw daily trading volume of roughly…

Continue Reading For This AI Drug Developer, Look Beyond the Rally

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

Joseph E Maakaron, assistant professor of medicine, Marie Hu, assistant professor of medicine, Najla El Jurdi, assistant professor of medicine University of Minnesota Twin Cities, Minneapolis, United States Correspondence to: maaka001{at}umn.edu Abstract Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during the past five years, boasting…

Continue Reading Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

Ncbi Wgs Portal

Login page for ncbi wgs portal is presented below. Log into ncbi wgs portal page with one-click or find related helpful links. Last Updated: 17th August, 2022 WGS – NCBI – NIH   www.ncbi.nlm.nih.gov/genbank/wgs Nov 13, 2017 – Whole Genome Shotgun (WGS) projects are genome assemblies of incomplete genomes or…

Continue Reading Ncbi Wgs Portal

Injectable Drugs Market Analysis of the Competitive Landscape, with a Forecast for 2027

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global injectable drugs market is relied upon to enlist a strong double-digit CAGR within the forecast period from 2019 to 2027. The market is majorly classified on the basis of drug-class, geography, molecule-type, and application. From the previous one entire…

Continue Reading Injectable Drugs Market Analysis of the Competitive Landscape, with a Forecast for 2027

Editas Medicine: Clinical Hold Lifted; Management Upbeat (NASDAQ:EDIT)

gorodenkoff/iStock via Getty Images The discovery of the CRISPR gene-editing tool has helped medical companies develop immunological defenses and curative systems against pathogens. Notable companies using this technology include CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (NASDAQ:EDIT). Editas has an expansive pipeline under research. It includes Vivo gene-edited…

Continue Reading Editas Medicine: Clinical Hold Lifted; Management Upbeat (NASDAQ:EDIT)

Mutation Generation Systems Market Analysis, Segment, Trends and Forecasts

AI-backed computer algorithms (more of sophisticated algorithms), better known as chatbots, are capable of conducting meaningful conversations (human-like) through option-based, textual, or voice-based input. The basic advantage of these chatbots would be smooth sailing on the part of patients in spite healthcare personnel being out of reach at times (due…

Continue Reading Mutation Generation Systems Market Analysis, Segment, Trends and Forecasts

Genentech DLBCL treatment gets FDA approval

Genentech, a part of the Roche Group, says the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy. Polivy (polatuzumab vedotin-piiq), in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large…

Continue Reading Genentech DLBCL treatment gets FDA approval

Multidrug resistance microbial therapy | VMRR

Introduction Antimicrobials are the most important and useful therapeutic discovery in the history of medicine. It allows living beings to survive the microbial disease, enhances invasive surgical procedures, ensures animal health, and protects the food chain since 1928 after the discovery of penicillin. However, the indiscriminate use of antibiotics and…

Continue Reading Multidrug resistance microbial therapy | VMRR

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the ‘Company’), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced an update on its financial results and recent business developments for the first half ended June…

Continue Reading Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

US approves BMS CAR-T in large B-cell lymphoma

Samit Hirawat, medical director of Bristol Myers Squibb. Bristol Myers Squibb has announced that the US Drug Evaluation Agency (FDA) has approved Breyanzi (lisocabtagene maraleucel; lisa-cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with large B-cell lymphoma (DLB), including diffuse large B-cell lymphoma…

Continue Reading US approves BMS CAR-T in large B-cell lymphoma

Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

liulolo/iStock via Getty Images Investment Thesis If you had invested in the CRISPR / Cas9 gene editing pioneer Intellia Therapeutics (NASDAQ:NTLA) five years ago, you would likely be well satisfied with your return to date – a ~285% return on your investment – although you may also feel that it…

Continue Reading Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

Relapsed/Refractory Anaplastic Large Cell Lymphoma

The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long….

Continue Reading Relapsed/Refractory Anaplastic Large Cell Lymphoma

A Novel COVID-19 Vaccine Using Modified Bacterial DNA

A visualization of the immune engineering process, from structure selection to authentic virus neutralization. Upper left: Analysis of interaction between SARS-CoV-2 and the ACE2 receptor revealed numerous contact residues along the receptor binding motif (RBM) ridgeline. Upper right: Focus was placed on residues comprising the FNCY patch, a conserved site…

Continue Reading A Novel COVID-19 Vaccine Using Modified Bacterial DNA

Stock Alert: Sesen Bio (SESN) Falling 20.69% in Pre-Market Hours for July 18

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange SESN – Market Data & News Trade Shares of Sesen Bio Inc. (NASDAQ:SESN) are on the…

Continue Reading Stock Alert: Sesen Bio (SESN) Falling 20.69% in Pre-Market Hours for July 18

Intellia and Regeneron Present – GuruFocus.com

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose,…

Continue Reading Intellia and Regeneron Present – GuruFocus.com

Plant-based Expression Systems are Gaining Mainstream Advantage

Industry adoption of plant-made biologics remains slow, but plant-based technology gains an advantage by mainstream exposure. While Chinese hamster ovary (CHO) cells are the workhorse of biologics production, other cell expression systems are starting to gain ground, such as plant-based expression systems. Though an older technology in and of itself,…

Continue Reading Plant-based Expression Systems are Gaining Mainstream Advantage

Xenazine (Tetrabenazine) – Oral: Uses, Side Effects, Dosages

What Is Xenazine? Xenazine (tetrabenazine) is a medication option used to treat abnormal and extra muscle movements in people with Huntington’s disease (HD). Xenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor. It’s thought to work by preventing VMAT2 from moving monoamines (naturally occurring brain chemicals) into vesicles. Neurons (nerve…

Continue Reading Xenazine (Tetrabenazine) – Oral: Uses, Side Effects, Dosages

Tramadol Therapy and CYP2D6 Genotype – Medical Genetics Summaries

Introduction Tramadol (brand names ConZip, Ultram, UltramER, Odolo) is an analgesic used to treat moderate to severe pain. It is used for a variety of pain conditions, including post-operative pain, cancer pain, and musculoskeletal pain. Tramadol is a centrally acting opioid analgesic with mu-opioid binding activity as well as weak…

Continue Reading Tramadol Therapy and CYP2D6 Genotype – Medical Genetics Summaries

Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S Phase 3 trial of ABNCoV2, a non-adjuvanted COVID-19 booster vaccine candidate, has been redesigned as comparator vaccine has now become available, enabling a double-blind, controlled study to demonstrate non-inferiority of ABNCoV2 to a licensed mRNA vaccine The fully sponsored trial will be initiated in August 2022, overall…

Continue Reading Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine Candidate

Novartis announces promising five-year data for leukaemia treatment Kymriah

Novartis has shared long-term, five-year follow-up results from its pivotal clinical phase 2 trial, ELIANA, evaluating Kymriah (tisagenlecleucel), the first-ever approved CAR T-cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). Kymriah is a one-off treatment designed to help patients’ immune…

Continue Reading Novartis announces promising five-year data for leukaemia treatment Kymriah

CISA Warned About Critical Vulnerabilities in Illumina’s DNA Sequencing Devices

The U.S. Cybersecurity and Infrastructure Security Agency (CISA) and Food and Drug Administration (FDA) have issued an advisory about critical security vulnerabilities in Illumina’s next-generation sequencing (NGS) software. Three of the flaws are rated 10 out of 10 for severity on the Common Vulnerability Scoring System (CVSS), with two others…

Continue Reading CISA Warned About Critical Vulnerabilities in Illumina’s DNA Sequencing Devices

FDA Flags Heart Inflammation Risk Over Novavax COVID-19 Vaccine

Staff with the U.S. Food and Drug Administration (FDA) on Friday flagged the risk of heart inflammation following the administration of the Novavax COVID-19 vaccine, although they concluded the shot reduces the risk of mild-to-severe COVID-19. In the company’s nearly 30,000 patient trial, conducted between December 2020 and September 2021, there…

Continue Reading FDA Flags Heart Inflammation Risk Over Novavax COVID-19 Vaccine

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade. The findings from the preclinical study were published today in Nature Nanotechnology. As the first-of-its-kind platform, the Microbubble-assisted UltraSound-guided…

Continue Reading First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Nirogacestat Yields Positive Findings in Progressing Desmoid Tumors

Findings from the phase 3 DeFi study indicated that treatment with nirogacestat met the trial’s end points in patients with progressing desmoid tumors. Investigators reported positive topline findings from the double-blind placebo controlled phase 3 DeFi trial (NCT03785964), assessing the use of nirogacestat as a treatment for adult patients with…

Continue Reading Nirogacestat Yields Positive Findings in Progressing Desmoid Tumors

Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

A group of researchers at Children’s Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing, which is designed to allow for precise editing of the CART with less risk of unwanted and unforeseen outcomes that may…

Continue Reading Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

Bispecific antibodies | Scientist Live

Bispecific antibodies: rising stars in antibody therapeutics Monoclonal antibodies (mAbs) are important therapeutic agents for the treatment of many human diseases, such as cancer, autoimmune diseases, cardiovascular diseases, asthma, and viral infections. Unlike monospecific mAbs, bispecific antibodies (bsAbs) are antibodies containing two antigen-binding sites and therefore can simultaneously target two…

Continue Reading Bispecific antibodies | Scientist Live

Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

This article was originally published here Curr Oncol Rep. 2022 May 16. doi: 10.1007/s11912-022-01278-0. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer….

Continue Reading Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

Researchers identify cellular serpins as host factors that restrict SARS-CoV-2 infection

The mass vaccination programs against coronavirus disease 2019 (COVID-19) received massive media attention and were widely credited for reducing the threat of the disease. However, many countries struggle to obtain enough doses to immunize their population, and some immunocompromised individuals are less protected by the vaccines. There is still a…

Continue Reading Researchers identify cellular serpins as host factors that restrict SARS-CoV-2 infection

Amyloid testing reaches a limited market

Never let it be said that the FDA does not have a sense of timing. Two days after Biogen pretty much gave up on its anti-amyloid drug Aduhelm, the US regulator has granted de novo clearance to the first in vitro diagnostic for amyloid plaques. The Lumipulse G β-Amyloid Ratio (1-42/1-40)…

Continue Reading Amyloid testing reaches a limited market

Covid, like TB, may keep coming

DR FAHEEM YOUNUS, chief of infectious diseases at the Maryland University, is on a mission to combat disinformation. In an exclusive interview, Younus expresses his concerns on how the pandemic could widen the gap between the haves and the have-nots. Excerpts: Tell us about the Covid situation in the US….

Continue Reading Covid, like TB, may keep coming

Cancer Discov: EGFR/FGFR dual target combination improves the clinical benefit of FGFR2 fusion cholangiocarcinoma

Treatment options for intrahepatic cholangiocarcinoma (ICC) are limited and the prognosis is usually poor after conventional chemotherapy. A variety of selective small-molecule FGFR1-3 kinase inhibitors are clinically effective, and the FDA has also approved the FGFR inhibitors pemigatinib and infigratinib for patients with ICC who have failed standard therapy and…

Continue Reading Cancer Discov: EGFR/FGFR dual target combination improves the clinical benefit of FGFR2 fusion cholangiocarcinoma

Delsym (Dextromethorphan) Oral: Uses, Side Effects, Dosages

What Is Delsym? Delsym (dextromethorphan) is an over-the-counter (OTC) cough syrup that is used often during cold and flu season to relieve cough.  Although Delsym has been available for a relatively long time, how it works is not completely known. However, medical experts believe that Delsym may work by mimicking…

Continue Reading Delsym (Dextromethorphan) Oral: Uses, Side Effects, Dosages

Indigenous Production of Industrially Important Recombinant Human Erythropoietin in Stable Huh-7 and CHO Cell Line

Recombinant human erythropoietin (rHuEPO) is one of the biopharmaceuticals that dominates the market due to the presence of large number of patients suffering from anemia associated with end-stage renal disease, cancer or AIDS. EPO is a glycoprotein mainly produced by kidney in adults and liver in fetus, involved in the…

Continue Reading Indigenous Production of Industrially Important Recombinant Human Erythropoietin in Stable Huh-7 and CHO Cell Line

Does Norepinephrine Metabolite DOPEGAL Turn Tau Toxic?

08 Apr 2022 What makes tau toxic? In the March 24 Nature Structural & Molecular Biology, researchers led by Keqiang Ye at Shenzhen Institute of Advanced Technology, China, suggest a new culprit, a norepinephrine metabolite known as DOPEGAL, which is produced only in the locus coeruleus (LC). The authors found…

Continue Reading Does Norepinephrine Metabolite DOPEGAL Turn Tau Toxic?

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient derived (PDX) models ex vivo, including diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer Single agent BMF-219 demonstrated pronounced anti-cancer activity…

Continue Reading Biomea Fusion Reports Preclinical Data on BMF-219 and Trial

Innovative site-specific anti-HER2 antibody-drug conjugate

Introduction Antibody-drug conjugates (ADCs) have been studied for decades as a promising cancer treatment. As compared to conventional chemotherapy, ADCs have a larger therapeutic window because of their ability to target antigen-expressing tumor cells.1 As ADC drug development technology continues to evolve, several ADC drugs are being introduced to the…

Continue Reading Innovative site-specific anti-HER2 antibody-drug conjugate

Your Source Of Daily World News Crypto Business Technology & Sports News

Cholangiocarcinoma, or bile duct most cancers, is lethal even when caught early. The 5-year survival rate amongst these identified early is 17% to 25%; for many sufferers, the speed is under 10%. Experts say the important thing to bettering these dismal statistics is to give attention to the various genetic…

Continue Reading Your Source Of Daily World News Crypto Business Technology & Sports News

What are the PRLR-SLICK cattle?

Earlier this month, a type of short-haired cattle, called PRLR-SLICK, was added to a very short list of animals given a low-risk assessment by the FDA’s Center for Veterinary Medicine (CVM). What’s so special about these cattle is that they are the first intentional genomic alteration (IGA) in an animal…

Continue Reading What are the PRLR-SLICK cattle?

Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL

During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy. Targeted OncologyTM: What are the recommended approaches for relapsed/refractory DLBCL in the second-line and subsequent therapies settings?…

Continue Reading Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL

Time for Proteomics To Shine

This article includes research findings that are yet to be peer-reviewed. Results are therefore regarded as preliminary and should be interpreted as such. Find out about the role of the peer review process in research here. For further information, please contact the cited source. Over the last 20 years, advances…

Continue Reading Time for Proteomics To Shine

Get Politics Out of Health Care

Medical freedom is a right that must be protected for all; it transcends politics and applies to people regardless of political party. Speaking with The New American at the Conservative Political Action Committee (CPAC) conference in Orlando, Florida, Dr. Robert Malone, the inventor of the mRNA and DNA vaccine core…

Continue Reading Get Politics Out of Health Care

Cho Cell Line Development & Engineering: Impact On Biopharmaceutical Production: Essay Example, 2571 words

1. Introduction The approval of Chinese hamster ovary (CHO) cell cultures for the manufacturing of protein therapeutic products modernized conventional medicine. CHO cells remained the workhorse for the production of monoclonal antibodies (mAbs) for the last at least 20 years for different reasons. First, CHO cells are easily adapting and…

Continue Reading Cho Cell Line Development & Engineering: Impact On Biopharmaceutical Production: Essay Example, 2571 words

Anaplastic Large Cell Lymphoma Presenting as Ulcerative Facial Mass: A Case Report – FullText – Case Reports in Oncology 2022, Vol. 15, No. 1

Anaplastic large cell lymphoma (ALCL) is a rare form of non-Hodgkin lymphoma (NHL) that can be aggressive with rapid speed, thus mandating a timely diagnosis to optimize treatment and deter progression. NHL classically presents with lymphadenopathy and constitutional symptoms. However, ALCL can present with nonspecific cutaneous manifestations with minimal or…

Continue Reading Anaplastic Large Cell Lymphoma Presenting as Ulcerative Facial Mass: A Case Report – FullText – Case Reports in Oncology 2022, Vol. 15, No. 1

‘Majority of Patients’ With Cholangiocarcinoma Still Receive Upfront Standard of Care Despite Recent FDA Drug Approvals

Despite treatment advancements and Food and Drug Administration (FDA) approvals of drugs in the cholangiocarcinoma (a type of bile duct cancer) space in recent years, there are still many patients with this disease who are not eligible for targeted therapies as a first treatment option, highlighting a significant need for…

Continue Reading ‘Majority of Patients’ With Cholangiocarcinoma Still Receive Upfront Standard of Care Despite Recent FDA Drug Approvals

DNAnexus Secures $200 Million Funding Led by Blackstone Growth to Advance its Biomedical Data-Driven Technology Platform for Precision Medicine

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#Bioinformatics—DNAnexus, Inc., a leading provider of cloud-based biomedical data analysis software serving the life sciences community, today announced a $200 million financing round to accelerate the global adoption of its technology, translating the world’s complex multi-omics and clinical data into tangible insights and personalized treatments. The round…

Continue Reading DNAnexus Secures $200 Million Funding Led by Blackstone Growth to Advance its Biomedical Data-Driven Technology Platform for Precision Medicine

Intellia gets upgrade at Brookline amid ‘unchanged’ patent risk on CRISPR/Cas9 technology

Andy/iStock via Getty Images Intellia Therapeutics (NTLA -3.1%) was upgraded by Brookline Capital Management to Buy from Hold with a $91 price target. Brookline analyst Leah Cann said the patent risk is unchanged, but the valuation has become attractive. In February, the U.S. Patent and Trademark Office backed the Broad…

Continue Reading Intellia gets upgrade at Brookline amid ‘unchanged’ patent risk on CRISPR/Cas9 technology

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

Lugano, Switzerland and Palo Alto, CA – Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, announced an…

Continue Reading Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

Failure to Warn Suit Against Implant Manufacturer Dismissed

On Monday a motion to dismiss was granted in an Eastern District of Tennessee lawsuit concerning failure to warn of potential side effects of Sientra Inc.’s breast implants. The plaintiff, per the opinion, underwent breast reconstruction after a double-mastectomy. After the procedure, the patient experience swelling indicative of breast implant…

Continue Reading Failure to Warn Suit Against Implant Manufacturer Dismissed

EDIT Stock Escalated Afterhours Following Favorable Decision by USPTO

Editas Medicine, Inc. (EDIT) is a leading genome editing company engaged in translating the potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing platforms into a vigorous treatment pipeline for people with unmet medical needs. The price of EDIT stock during the regular trading on February 28, 2022, was $17.1 with…

Continue Reading EDIT Stock Escalated Afterhours Following Favorable Decision by USPTO

Nuprobe USA Inc. Quality Assurance Manager

Quality Assurance Manager- Molecular NGS, PCR, IVD Quality Assurance ManagerHouston TX NuProbe USA Inc. is looking for a Quality Assurance Manager to lead the Quality program to establish and maintain compliance to ISO: 9001, ISO: 13485, and FDA 21 CFR Part 820 Quality System Regulations. NuProbe USA is a rapidly…

Continue Reading Nuprobe USA Inc. Quality Assurance Manager

Pathogenomix Developing Infectious Disease Testing Platform Enabled by Cloud-Based Analytics, NGS

NEW YORK — Pathogenomix is combining sequencer-agnostic, cloud-based analytics software with 16S rRNA gene sequencing to enable hospital laboratories to identify the pathogens behind life-threatening bacterial infections. Though no NGS-based tests have obtained full US Food and Drug Administration authorization to identify infectious disease pathogens, Pathogenomix said it is on…

Continue Reading Pathogenomix Developing Infectious Disease Testing Platform Enabled by Cloud-Based Analytics, NGS

Bristol Myers’ (BMY) Breyanzi sBLA Gets FDA’s Priority Review

This story originally appeared on Zacks Bristol-Myers Squibb Company BMY announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking approval for its CD19-directed CAR-T cell therapy, Breyanzi (lisocabtagene maraleucel), for an expanded use. – Zacks The sBLA seeks approval of Breyanzi…

Continue Reading Bristol Myers’ (BMY) Breyanzi sBLA Gets FDA’s Priority Review

Postdoctoral Fellowship in Bioinformatics/Statistics – UN Jobs Vacancies Tenders

*Applications may be reviewed on a rolling-basis and this posting could close before the deadline. ARS Office/Lab and Location: A postdoctoral fellowship in bioinformatics/statistics is currently available with the U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), Southern Regional Research Center located in New Orleans, Louisiana. Research Project: Food allergy costs the US $25…

Continue Reading Postdoctoral Fellowship in Bioinformatics/Statistics – UN Jobs Vacancies Tenders

C1QBP Antibody | Cell Signaling Technology

Limited Uses Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer’s terms and conditions that are in addition to, or different from, those contained herein, unless separately…

Continue Reading C1QBP Antibody | Cell Signaling Technology

Sesen Bio (SESN) falls 5.75% on Moderate Volume February 2

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange SESN – Market Data & News Trade Today, Sesen Bio Inc. Inc’s (NASDAQ: SESN) stock fell…

Continue Reading Sesen Bio (SESN) falls 5.75% on Moderate Volume February 2

Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Last week, the California-based biotech shared that a handful of trials for magrolimab in combination with azacytidine had been placed on a partial clinical hold because of an “apparent imbalance” in adverse reactions…

Continue Reading Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

In Brief This Week: Innovent, Senhwa Biosciences, Oric Pharmaceuticals, Dizal Pharmaceutical

NEW YORK – Innovent this week said that pemigatinib (Pemazyre) was approved in Hong Kong as a treatment for locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. The approval was based on the Phase II FIGHT-202 study, which showed a 37 percent response rate for cholangiocarcinoma patients treated…

Continue Reading In Brief This Week: Innovent, Senhwa Biosciences, Oric Pharmaceuticals, Dizal Pharmaceutical

Xenotransplantation: Argentina is about to produce genetically modified animals for human transplants

While the international medical community celebrates the first successful xenotransplantation, in Argentina two research teams from public universities are preparing to produce genetically modified animals so that their organs are suitable for human transplants and the first pigs of this type would be obtained at the end of this year…

Continue Reading Xenotransplantation: Argentina is about to produce genetically modified animals for human transplants

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin’s lymphoma in the United States, with approximately 40% of first-line DLBCL chemoimmunotherapy attempts failing. The FDA approved a new type of antibody-drug conjugate (ADC), Zynlonta (loncastuximab tesirine), once called ADCT-402, on April 23, 2021, for relapsed or…

Continue Reading Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Guardant Health Staff Site Reliability Engineering / DevOps: Bioinformatics

Covid Vaccination Policy:  Starting January 7, 2022, Guardant Health will require all employees to be fully vaccinated to either (a) establish that they have been fully vaccinated against COVID-19; or (b) request and obtain an approved exemption from Guardant’s COVID-19 U.S. Vaccination Policy as a reasonable accommodation, as consistent with applicable…

Continue Reading Guardant Health Staff Site Reliability Engineering / DevOps: Bioinformatics

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

This story originally appeared on Zacks Editas Medicine, Inc. EDIT has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness. – Zacks The company is evaluating…

Continue Reading Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Officials with the FDA have granted both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation to C-CAR039, a novel autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients…

Continue Reading FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

– Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) – – New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheus’ precision approach and extends CDx patent coverage into 2040 – – Company to present today…

Continue Reading Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

Basilea reports on portfolio progress made in 2021

Achieved important Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) milestones Added new clinical candidate BAL0891 to oncology pipeline and advanced clinical programs with derazantinib and lisavanbulin Basel, January 06, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases…

Continue Reading Basilea reports on portfolio progress made in 2021

Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

H.C. Wainwright BioConnect 2022 Conference January 10-13, 2022 Biotech Showcase Virtual Conference January 17-19, 2022 CRANFORD, N.J., Jan. 4, 2022 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on…

Continue Reading Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

Sr. Manager of Manufacturing – Resumetojobs.com

NuProbe USA is seeking an experienced Sr. Manager, In-Vitro Diagnostics Operations who will be responsible for all aspects of manufacturing, including design transfer of newly developed products from research & development. The successful candidate will control production planning, scheduling and forecasting. The candidate will lead continuous improvements in manufacturing as…

Continue Reading Sr. Manager of Manufacturing – Resumetojobs.com

Illumina MiSeq Instruments Preventative Maintenance

From: Federal Government(Federal) Start Date 27 May, 2021 (7 months ago) Due Date 07 Jun, 2021 (6 months ago) Opportunity Type Bid Notification Opportunity Identifier FDA-CSS-1241810 Customer / Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Location Jefferson , AR 72079 USA Illumina MiSeq Instruments Preventative Maintenance per the attached Combined…

Continue Reading Illumina MiSeq Instruments Preventative Maintenance

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Brem Looks at Multiple Treatments for Patients With DLBCL

During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma. Targeted Oncology™: What therapeutic options would you consider at…

Continue Reading Brem Looks at Multiple Treatments for Patients With DLBCL

Bioinformatics Engineer/Senior Engineer – Cambridge Massachusetts

Flagship Pioneering has launched a privately held, biotechnology company that is pioneering novel diagnostics for cancer. This new company, Harbinger Oncology, is a highly dynamic, entrepreneurial, and innovation-driven organization seeking to hire a Bioinformatics Engineer/Senior Engineer to join our team. Flagship Pioneering conceives, creates, resources, and grows first-in-category life sciences…

Continue Reading Bioinformatics Engineer/Senior Engineer – Cambridge Massachusetts

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Introduction Rituximab (Rituxan; Genentech) is a chimeric anti-CD20 monoclonal antibody widely used in non-Hodgkin lymphoma (NHL) treatment.1 Worldwide, rituximab is recommended for a variety of B-cell malignancies,1,2 and it has a well-established efficacy and safety profile, with more than 4 million patients treated.1,3 In the United States, rituximab is approved…

Continue Reading Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Guardant Health Senior DevOps Engineer: Bioinformatics

Covid Vaccination Policy:  Starting January 7, 2022, Guardant Health will require all employees to be fully vaccinated to either (a) establish that they have been fully vaccinated against COVID-19; or (b) request and obtain an approved exemption from Guardant’s COVID-19 U.S. Vaccination Policy as a reasonable accommodation, as consistent with applicable…

Continue Reading Guardant Health Senior DevOps Engineer: Bioinformatics

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S….

Continue Reading Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia